## MRK: Merck & Company, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.80 indicates fundamental undervaluation. Quality metrics strong (ROE 40%, ROA 14%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-11.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($95.41)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Schroder Investment Management Group Has $117.81 Million Holdings in Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251130T122235 | Somewhat-Bullish | Relevance: 99%
- Schroder Investment Management Group reduced its stake in Merck & Co., Inc. by 9.8% in Q2, now holding 1,488,218 shares valued at $117.81 million. Concurrently, a Merck executive sold shares, decreasing his ownership by nearly 26%. The company reported strong quarterly earnings, beating estimates, and raised its quarterly dividend and full-year guidance.

**2. M&T Bank Corp Decreases Position in Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251202T130358 | Somewhat-Bullish | Relevance: 99%
- M&T Bank Corp significantly decreased its stake in Merck & Co., Inc. ($MRK) by 19.4% in the second quarter of 2025. This comes as Merck reported strong Q3 earnings, beating analyst expectations, and increased its quarterly dividend. Analyst sentiment toward Merck is generally positive, with a "Moderate Buy" consensus rating and an average price target of $107.06.

**3. Distillate Capital Partners LLC Sells 58,061 Shares of Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251201T102421 | Neutral | Relevance: 99%
- Distillate Capital Partners LLC reduced its stake in Merck & Co., Inc. by 9.3% during the second quarter, selling 58,061 shares, yet the stock remains its second-largest holding. Meanwhile, other institutional investors like Little House Capital LLC, Longfellow Investment Management Co. LLC, and MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH either boosted their holdings or made significant purchases. The article also covers insider selling, share price performance, recent earnings, dividend increases, and analyst ratings for Merck & Co., Inc.

**4. Form 424B5 Merck & Co., Inc.**
- Source: StreetInsider | 20251201T131400 | Somewhat-Bullish | Relevance: 99%
-  Merck & Co., Inc. is offering various series of floating and fixed rate notes in denominations of $2,000 and integral multiples of $1,000. The proceeds will be used for general corporate purposes, including potentially funding a portion of the cash consideration for the acquisition of Cidara Therapeutics, Inc. The offering highlights risk factors associated with investing in the notes, including market volatility and the potential for special mandatory redemption if the Cidara acquisition is not completed.

**5. Merck Showcases Data For Alzheimer's Disease Candidates Mk-2214 And Mk-1167 At Ctad 2025**
- Source: TradingView | 20251201T130635 | Somewhat-Bullish | Relevance: 98%
- Merck & Co Inc (MRK) announced that it will showcase data for its Alzheimer's disease candidates, MK-2214 and MK-1167, at the Clinical Trials on Alzheimer's Disease (CTAD) conference in 2025. This news highlights Merck's ongoing commitment to developing treatments for Alzheimer's.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $120 | $105 | +14% |
| 2025-12-02 | Goldman Sachs | $120 | $92 | +30% |
| 2025-11-24 | Wells Fargo | $125 | $90 | +39% |
| 2025-11-18 | Deutsche Bank | $111 | $110 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Outperform |
| 2025-12-02 | Goldman Sachs | main | Buy |
| 2025-11-24 | Wells Fargo | up | Overweight |
| 2025-11-18 | Deutsche Bank | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.09M) |
| Sells | 2 ($1.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.2% (-0.3%)
- Blackrock Inc.: 8.7% (-1.6%)
- State Street Corpora: 4.8% (-0.3%)
- Wellington Managemen: 3.0% (-2.0%)
- JPMORGAN CHASE & CO: 2.8% (+121.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 4 raises (avg +21%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.80 indicates undervaluation relative to growth. Quality metrics strong (ROE 40%, ROA 14%, margin 30%). Balance sheet: $6.8B free cash flow. Analyst sentiment positive (4 raises, avg +21%). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $243.8B |
| Beta | 0.30 |
| 52W Range | $73.31 - $105.84 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.80 |
| Forward P/E | 11.8 |
| Current P/E | 11.3 |
| YoY Growth | -4.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 16.4% to 5.0% (-11.4% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 90th percentile. MRS_5 (-3.1%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.9% shows strong absolute momentum above own 20MA. Outperforming sector by 5.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.72), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.99% (CS: 91) | Strong |
| RSI_14 | 66.3 | Neutral |
| MACD Histogram | 0.72 | Bullish |
| vs SMA20 | 1.069x | Above |
| vs SMA50 | 1.135x | Above |
| vs SMA200 | 1.194x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $101.03
- **Stop Loss:** $95.41 (5.6% risk)
- **Target:** $112.27 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 177
- **Position Value:** $17,882.31
- **Portfolio %:** 17.88%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $2.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.58 | +9.9% |
| 2025Q2 | $2.03 | $2.13 | +5.0% |
| 2025Q1 | $2.14 | $2.22 | +4.0% |
| 2024Q4 | $1.67 | $1.72 | +3.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*